Thymogen is the trade name for a synthetic dipeptide, L-glutamyl-L-tryptophan (Glu-Trp), developed in the Soviet Union and Russia as a “thymic bioregulator” — a small peptide meant to mimic natural thymus-derived signals that influence immune cell activity. It has been sold in Russia as an injectable solution and a nasal spray for decades, but it has almost no presence in Western peer-reviewed clinical literature, no FDA or EMA approval, and no regulatory status outside the former Soviet sphere.
Research snapshot
| Peptide category | Synthetic dipeptide “thymic bioregulator,” developed in the Soviet Union/Russia |
| Primary research interest | Immune-modulation via mimicking natural thymus-derived signaling peptides |
| Highest available evidence | Decades-long Russian clinical/marketing use; almost no presence in Western peer-reviewed clinical literature |
| Human research available | Used clinically in Russia for decades (injectable solution and nasal spray); not evaluated through FDA/EMA-style clinical trials |
| Development status | Established Russian pharmaceutical product; first synthesized and studied in the early-to-mid 1980s |
| Regulatory status | Registered and available as a prescription pharmaceutical in Russia; not FDA-approved, not recognized as a US dietary supplement, no EU marketing authorization |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Thymogen |
| Alternative names | Timogen (alternate transliteration) |
| Peptide sequence | Glu-Trp (L-glutamyl-L-tryptophan) |
| Amino-acid length | 2 (dipeptide) |
| Molecular formula | Not independently re-verified in this pass |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| Peptide class | Thymic bioregulator peptide (Khavinson/Morozov research line, distinct product line from the Cytomax “organ-named” series) |
| Primary biological target | Proposed immune-modulatory activity affecting T-lymphocyte maturation/function; not established via modern receptor-level human data |
| Developer or originator | Military Medical Academy, Leningrad/St. Petersburg — Vladimir Khavinson and Vyacheslav Morozov, early-to-mid 1980s |
| Development status | Marketed prescription pharmaceutical in Russia only |
What it is
Thymogen (also transliterated Timogen) is a two-amino-acid peptide, glutamyl-tryptophan, first synthesized and studied at the Military Medical Academy in Leningrad/St. Petersburg in the early-to-mid 1980s by researchers including Vladimir Khavinson and Vyacheslav Morozov, who were investigating short peptide extracts of the thymus gland (the organ that matures T-lymphocytes, the immune cells responsible for much of adaptive immunity). It belongs to the same Russian “thymomimetic” or “cytomedine” research tradition that produced related thymic extract peptides such as Thymalin and Thymulin.
Unlike thymosin alpha-1 or thymulin, which are naturally occurring peptides isolated directly from thymus tissue, Thymogen is a fully synthetic dipeptide that was designed to reproduce part of the biological activity attributed to those natural thymic factors in a simpler, more stable molecule. It was registered as a pharmaceutical product in Russia (marketed under names including Thymogen and Timogen) for use as an immunomodulator, primarily in the context of recovery from infection, wound healing, and general “immune correction,” and it remains available by prescription in Russia today.
Development and most of the supporting research took place in Russian-language medical journals and Soviet/Russian pharmacology literature that has not been independently replicated or systematically reviewed in indexed, English-language, peer-reviewed journals. This is an important limitation: much of what circulates about Thymogen in English is secondhand summary of Russian sources, vendor material, or peptide-community writeups rather than material that can be independently verified against a primary study.
Thymogen is not an FDA-approved drug, is not a dietary supplement recognized by U.S. or EU regulators, and has no established role in Western clinical immunology. It should be understood as a regionally used pharmaceutical with a research history that is difficult to verify outside Russian-language sources, not as an internationally validated immune therapy.
How does it work?
Plain-English explanation
The thymus gland is where immune cells called T-lymphocytes mature and learn to recognize threats. As people age, or during illness, thymus activity and output can decline. The general idea behind “thymic bioregulator” peptides like Thymogen is that a very small peptide signal might nudge immune cells to behave more the way they would under healthy thymus signaling — essentially trying to recreate a piece of a natural biological message using a small, synthetic stand-in. This is a hypothesis rooted in the broader Russian “bioregulator” peptide research tradition rather than a mechanism confirmed by Western immunology.
Technical explanation
Thymogen is described in the primary Russian-language literature as an immunomodulator that influences T-cell differentiation and cytokine production, and as having reported effects on phagocytic activity (the ability of certain white blood cells to engulf pathogens) and on markers of oxidative stress and cell repair in some animal and cell-based studies. Specific receptor targets and a defined molecular pathway have not been clearly established in independently verifiable, indexed literature. As a short, unmodified dipeptide, Thymogen would be expected to have a very short biological half-life and limited oral bioavailability, which is consistent with its use in Russia primarily as an injectable or intranasal product rather than an oral one. No established or reliably sourced pharmacokinetic data (half-life, bioavailability by route) was identified in accessible English-language sources.
Potential benefits and research applications
General immune modulation
What is being investigated: whether Thymogen can support recovery of immune parameters after illness, surgery, or in older adults with reduced thymic function. How the effect might occur: by supplying a peptide signal proposed to influence T-cell activity and cytokine balance. Evidence: this claim rests almost entirely on Russian-language clinical and pharmacological literature that could not be independently verified here, plus community and vendor summaries repeating those claims. Strength: this has not been established in independently verifiable, peer-reviewed, English-language human research. Limitation: without access to and independent evaluation of the original Russian trial data, the size, quality, and reproducibility of any human findings cannot be confirmed.
Wound healing and recovery support
What is being investigated: use of Thymogen (often alongside other thymic peptides) in supporting recovery from infection or tissue injury, a traditional application in Russian clinical practice. How the effect might occur: proposed immune-modulating and tissue-repair-supporting activity. Evidence: practitioner and Russian clinical-practice reports; some cited animal or laboratory work referenced in secondary sources. Strength: has not been established in Western peer-reviewed clinical trials. Limitation: “Widely repeated online, but its original source could not be verified” applies to many of the specific claims made about this use on peptide information and vendor sites.
Anti-aging / geroprotective interest
What is being investigated: whether short bioregulator peptides like Thymogen might have broader effects on aging biomarkers, an idea promoted heavily by the Khavinson research group and associated Russian institutes. How the effect might occur: proposed general influence on gene expression and cellular regulation, sometimes described using the term “peptide bioregulation.” Evidence: primarily theoretical and drawn from a body of work concentrated in a small number of affiliated Russian research groups rather than broad, independently replicated science. Strength: has not been established; this application should be considered speculative. Limitation: independent replication outside the originating research group is limited or not identifiable in accessible literature.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
Russian pharmaceutical labeling and Russian-language clinical literature reportedly describe Thymogen courses using intramuscular injection and intranasal solution formats, but this content operates on the basis of independently verifiable, accessible sourcing, and no primary Russian clinical trial document with dosing data could be directly reviewed and confirmed here. Amounts and schedules attributed to Thymogen on English-language peptide and vendor sites (commonly citing figures in the range of roughly 100 micrograms per day by injection for short courses) are widely repeated online, but their original source could not be verified against an accessible, checkable primary document.
Amounts studied in animal research
Not consistently reported. Secondary sources reference unspecified Russian animal and cell-based pharmacology studies, but specific dose, species, and route details could not be independently verified from accessible sources.
Practitioner and community-reported protocols
Peptide-community and vendor sites (community/vendor-reported tier) commonly describe short injectable courses (often described as roughly 7 to 10 days) at low microgram-range daily amounts, sometimes repeated in cycles. These figures appear consistently across multiple non-primary sources without a traceable original clinical citation, which meets the definition of “widely repeated online, but its original source could not be verified.” No established or reliably sourced dosing information from an independently verifiable primary source was identified for this entry.
What circulates E5
No dosing figure attributed to Thymogen could be traced back to an independently verifiable primary source for this entry. Vendor and community peptide sites commonly repeat short injectable courses at low microgram-range daily amounts (often describing roughly 7-to-10-day courses), but these figures are widely repeated online without an identifiable, checkable original citation, so they are documented here only as claims in circulation, not as established dosing.
Because the underlying Russian clinical and regulatory documentation could not be directly reviewed for this entry, no established or reliably sourced dosing information was identified that could be confirmed independently.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Documented, independently verifiable human safety data for Thymogen is sparse in accessible English-language sources. Russian labeling reportedly lists the product as generally well tolerated with rare local injection-site reactions, but this could not be independently confirmed here. As with any unregulated or foreign-sourced peptide product obtained outside a pharmacy supply chain, general risks apply: uncertain purity and identity, mislabeled concentration, contamination, and lack of sterility assurance for injectable material obtained outside verified pharmaceutical channels. Because Thymogen is described as an immune-modulating agent, theoretical concerns about interactions with immunosuppressive or immune-stimulating medications, or with autoimmune conditions, have not been formally studied and should be treated as an open question rather than a resolved one. Long-term safety data outside its country of origin has not been established.
Regulatory and developmental status
Thymogen is registered and available as a prescription pharmaceutical in Russia, where it has a decades-long marketing history; it is not an FDA-approved drug, is not recognized as a dietary supplement in the United States, and has no marketing authorization in the European Union. Its regulatory footprint outside the former Soviet sphere is essentially nonexistent, and any product sold as “Thymogen” in other markets is being distributed outside standard pharmaceutical regulatory oversight for that jurisdiction. Status verified as of the date below.
Frequently asked questions
What is Thymogen?
Thymogen is a synthetic two-amino-acid peptide (glutamyl-tryptophan) developed in Russia as a thymus-mimicking immunomodulator, sold there as a prescription pharmaceutical.
How does Thymogen work?
It is proposed to influence T-lymphocyte activity and immune signaling in a manner modeled on natural thymus-derived factors, though the specific molecular mechanism has not been clearly established in independently verifiable literature.
What dosage has been studied in humans?
No independently verifiable, accessible primary source with confirmed human dosing data was identified for this entry; figures circulating online could not be traced to a checkable original source.
What dosage information circulates online?
Vendor and community sources commonly describe short injectable courses at low microgram-range daily amounts, but these figures are widely repeated without an identifiable original citation.
Has Thymogen been studied in humans?
Russian-language clinical literature reportedly exists, but it could not be independently accessed and verified for this entry, so the strength and quality of any human evidence cannot be confirmed here.
What side effects have been reported?
Independently verifiable safety data is limited; Russian labeling reportedly describes it as generally well tolerated, but this has not been independently confirmed.
Is Thymogen approved for use?
It is approved and sold by prescription in Russia only. It has no FDA, EMA, or other Western regulatory approval or recognized supplement status.
How strong is the evidence overall?
Weak from a Western, independently verifiable standpoint. Most available material is secondary, vendor, or community-sourced summary of Russian-language claims that could not be checked against primary documents here.
What remains unknown about Thymogen?
Independently verifiable human dosing data, a confirmed molecular mechanism, long-term safety data outside Russia, and consistent chemical-identifier data across databases all remain unresolved or unconfirmed.
Bottom line
Thymogen is a real, decades-old Russian pharmaceutical — a simple synthetic dipeptide studied within a specific national research and regulatory tradition that has not been substantially cross-verified in Western, independently accessible clinical literature. Outside Russia, most of what circulates about it online is vendor and community repetition of claims that could not be traced back to an original, checkable source for this entry. No established or reliably sourced dosing information was independently confirmed here, chemical identifiers conflict across commercial databases, and it carries no Western regulatory status. Anyone encountering Thymogen products outside Russia should treat the surrounding claims as unverified pending access to and independent evaluation of primary Russian source material.